<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>MDT Report</title>
  <style>
    :root {
      --border: #e5e7eb;
      --muted: #6b7280;
      --bg: #ffffff;
      --card: #ffffff;
      --soft: #f7f7f8;
      --accent: #2563eb;
    }
    body { font-family: -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif; margin: 24px; background: var(--bg); }
    h1 { font-size: 20px; margin: 0 0 12px 0; }
    h2 { font-size: 16px; margin: 0 0 10px 0; }
    h3 { font-size: 14px; margin: 10px 0 6px 0; }
    .meta { color: var(--muted); font-size: 13px; margin-bottom: 14px; }
    .cols { display: grid; grid-template-columns: 1fr 1fr; gap: 12px; }
    .card { border: 1px solid var(--border); border-radius: 12px; padding: 12px 14px; background: var(--card); }
    details { border: 1px solid var(--border); border-radius: 12px; padding: 10px 12px; background: var(--card); }
    summary { cursor: pointer; font-weight: 600; }
    pre { white-space: pre-wrap; word-wrap: break-word; background: var(--soft); padding: 12px; border-radius: 10px; overflow-x: auto; }
    .mono { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, "Liberation Mono", "Courier New", monospace; }
    .mt { margin-top: 12px; }
    .hint { color: var(--muted); font-size: 12px; margin-top: 6px; }
    .warn { color: #b45309; font-weight: 600; }
    table.grid { width: 100%; border-collapse: collapse; font-size: 13px; }
    table.grid th, table.grid td { border: 1px solid var(--border); padding: 8px; vertical-align: top; }
    table.grid th { background: #f3f4f6; text-align: left; }
    /* References section styling */
    .refs-section { border: 1px solid var(--border); border-radius: 12px; padding: 16px; background: var(--card); }
    .refs-title { font-size: 16px; font-weight: 700; color: #1f2937; margin: 0 0 16px 0; padding-bottom: 8px; border-bottom: 2px solid var(--accent); }
    .ref-category { margin-bottom: 16px; }
    .ref-cat-header { font-size: 14px; font-weight: 600; color: #374151; margin-bottom: 10px; padding: 6px 10px; background: linear-gradient(135deg, #f3f4f6 0%, #e5e7eb 100%); border-radius: 6px; }
    .ref-entry { margin-bottom: 10px; padding: 10px 12px; background: #fafafa; border-radius: 8px; border-left: 3px solid var(--accent); }
    .ref-tag { font-family: ui-monospace, SFMono-Regular, Menlo, Monaco, Consolas, monospace; font-size: 12px; font-weight: 600; color: var(--accent); margin-bottom: 6px; word-break: break-all; }
    .ref-details { font-size: 13px; color: #4b5563; line-height: 1.6; }
    .ref-detail-line { margin-bottom: 2px; }
    /* Category-specific colors */
    .ref-guidelines .ref-entry { border-left-color: #059669; }
    .ref-guidelines .ref-tag { color: #059669; }
    .ref-literature .ref-entry { border-left-color: #7c3aed; }
    .ref-literature .ref-tag { color: #7c3aed; }
    .ref-clinical-trials .ref-entry { border-left-color: #dc2626; }
    .ref-clinical-trials .ref-tag { color: #dc2626; }
    .ref-clinical-reports .ref-entry { border-left-color: #d97706; }
    .ref-clinical-reports .ref-tag { color: #d97706; }
    /* Mermaid chart styling */
    .mermaid-container { border-color: #10b981; }
    .mermaid-container > summary { color: #059669; }
    .mermaid-chart { padding: 16px; background: linear-gradient(135deg, #f0fdf4 0%, #ecfdf5 100%); border-radius: 10px; margin-top: 10px; overflow-x: auto; }
    .mermaid-chart svg { max-width: 100%; height: auto; }
    /* Dark mode support */
    @media (prefers-color-scheme: dark) {
      :root {
        --border: #374151;
        --muted: #9ca3af;
        --bg: #111827;
        --card: #1f2937;
        --soft: #374151;
        --accent: #60a5fa;
      }
      body { color: #f3f4f6; }
      h1, h2, h3 { color: #f9fafb; }
      table.grid th { background: #374151; color: #f3f4f6; }
      .refs-title { color: #f9fafb; }
      .ref-cat-header { background: linear-gradient(135deg, #374151 0%, #4b5563 100%); color: #f3f4f6; }
      .ref-entry { background: #374151; }
      .ref-details { color: #d1d5db; }
      .mermaid-chart { background: linear-gradient(135deg, #1f2937 0%, #374151 100%); }
      .stats-card { background: linear-gradient(135deg, #1e3a5f 0%, #1e293b 100%) !important; border-color: #0ea5e9 !important; }
      .stats-card h2 { color: #7dd3fc !important; }
    }
    /* Print button */
    .print-btn {
      position: fixed; top: 20px; right: 20px; z-index: 1000;
      padding: 10px 18px; cursor: pointer;
      background: linear-gradient(135deg, #2563eb 0%, #1d4ed8 100%);
      color: white; border: none; border-radius: 8px;
      font-size: 14px; font-weight: 600;
      box-shadow: 0 2px 8px rgba(37, 99, 235, 0.3);
      transition: all 0.2s ease;
    }
    .print-btn:hover { background: linear-gradient(135deg, #1d4ed8 0%, #1e40af 100%); transform: translateY(-1px); box-shadow: 0 4px 12px rgba(37, 99, 235, 0.4); }
    .print-btn:active { transform: translateY(0); }
    /* Print-friendly styles */
    @media print {
      body { margin: 0; background: white; }
      .card, details { border: 1px solid #ccc; page-break-inside: avoid; }
      details[open] > summary ~ * { display: block; }
      .mermaid-chart { page-break-inside: avoid; }
      .stats-card { background: #f0f9ff !important; -webkit-print-color-adjust: exact; print-color-adjust: exact; }
      .no-print { display: none !important; }
    }
    /* Responsive layout */
    @media (max-width: 768px) {
      body { margin: 12px; }
      .cols { grid-template-columns: 1fr; }
      table.grid { font-size: 11px; }
      table.grid th, table.grid td { padding: 4px; }
    }
  </style>
</head>
<body>
  <button onclick="window.print()" class="print-btn no-print">ğŸ–¨ï¸ Print Report</button>
  <h1>OMGs / MDT Report</h1>
  <div class='card stats-card' style='background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%); border: 2px solid #0ea5e9; margin-bottom: 16px;'>
<h2 style='margin-top: 0; color: #0369a1;'>ğŸ“Š Pipeline Execution Statistics</h2>
<div style='margin-bottom: 12px;'>
<strong>ğŸ¯ Mode:</strong> <code style='background: #e0f2fe; padding: 2px 8px; border-radius: 4px; font-weight: 600;'>omgs</code>
</div>
<div style='margin-bottom: 12px;'>
<strong>â±ï¸ Total Execution Time:</strong> 122.0 seconds (2åˆ†1ç§’)
</div>
<div style='margin-bottom: 12px;'>
<strong>ğŸ”¢ Total Tokens:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li>Input: 115,602</li>
<li>Output: 5,011</li>
<li>Total: 120,613</li>
</ul>
</div>
<div style='margin-bottom: 8px;'>
<strong>ğŸ¤– Models Used:</strong>
<ul style='margin: 6px 0 0 20px; padding: 0;'>
<li style='margin-bottom: 6px;'>
<strong>gpt-5.1 (Azure)</strong>: 
23 calls, 
120,613 tokens 
(115,602 in / 5,011 out)
</li>
</ul>
</div>
</div>
  <div class="meta">
    <div><b>Timestamp</b>: 2026-01-22_18-35-45</div>
  </div>

  <div class="cols mt">
    <div class="card">
      <h2>Final MDT Output</h2>
      <pre>Final Assessment:
Disseminated highâ€‘grade serous ovarian carcinoma, HRDâ€‘positive and BRCAâ€‘wildtype on NGS, currently in radiologic remission on firstâ€‘line PARP maintenance with acceptable blood counts, organ function, and tumor markers [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB] [@OH2201222 | Genomics]. Key uncertainties are exact FIGO stage, full pathology/IHC characterization, and optimal total duration of maintenance within the guidelineâ€‘supported 2â€“3â€‘year window [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]. Updated imaging beyond 2022â€‘10â€‘25 and longitudinal marker/symptom data are still needed to confirm ongoing remission [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].

Core Treatment Strategy:
- Continue current firstâ€‘line PARP maintenance toward finite 2â€“3â€‘year duration, with regular CBC, chemistries, and toxicity review [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].  
- Check CA125Â±HE4 at each followâ€‘up visit to establish trends and support early detection of biochemical relapse [@20230109|9701878 | LAB].  
- Obtain contrastâ€‘enhanced CT chest/abdomen plus pelvic MRI now to document current remission baseline for surveillance [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  
- Retrieve and finalize FIGO stage and full pathology/IHC (I2021â€‘07819), integrating HRDâ€‘positive, BRCAâ€‘wildtype NGS into the staging summary [@OH2201222 | Genomics].  

Change Triggers:
- If CA125/HE4 rise or new symptoms develop, advance imaging timing and consider FDG PET/CT for occult or equivocal disease [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].  
- If CT/MR or PET/CT demonstrates recurrence, reclassify line of therapy and transition from maintenance to appropriate systemic relapse management pathway.</pre>
<div class='refs-section mt'>
<h3 class='refs-title'>References</h3>
<div class='ref-category ref-guidelines'>
<div class='ref-cat-header'>ğŸ“‹ Guidelines</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: esmo_cpg_epithelialovarian_2023__v00000000, Page 8</div>
<div class='ref-detail-line'>Content: MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-</div>
<div class='ref-detail-line'>ity...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Document: nccn_ovariancancer_v3_2025__v00000000, Page 15</div>
<div class='ref-detail-line'>Content: based chemotherapy,n</div>
<div class='ref-detail-line'>preferred for first</div>
<div class='ref-detail-line'>recurrence...</div>
</div>
</div>
</div>
<div class='ref-category ref-literature'>
<div class='ref-cat-header'>ğŸ“š Literature</div>
</div>
<div class='ref-category ref-clinical-trials'>
<div class='ref-cat-header'>ğŸ”¬ Clinical Trials</div>
</div>
<div class='ref-category ref-clinical-reports'>
<div class='ref-cat-header'>ğŸ“„ Clinical Reports</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|5600622 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|5600622 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN) PLTåˆ†å¸ƒå®½åº¦ 10 % (PDW) å—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|8300382 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|8300382 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT) å°¿ç´  4.65 mmol/l (UREA) ä¹³é…¸è„±æ°¢é…¶ 267 U/L...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@20230109|9701878 | LAB]</div>
<div class='ref-details'>
<div class='ref-detail-line'>LAB ID: 20230109|9701878 | Date: 2023-01-09</div>
<div class='ref-detail-line'>Content: ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125) äººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@OH2201222 | Genomics]</div>
<div class='ref-details'>
<div class='ref-detail-line'>Genomics ID: OH2201222 | Date: 2022-01-24</div>
<div class='ref-detail-line'>Content: HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-09-27|CT | CT]</div>
<div class='ref-details'>
<div class='ref-detail-line'>CT ID: 2022-09-27|CT | Date: 2022-09-27</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒ...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-09-29|CT | CT]</div>
<div class='ref-details'>
<div class='ref-detail-line'>CT ID: 2022-09-29|CT | Date: 2022-09-29</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°...</div>
</div>
</div>
<div class='ref-entry'>
<div class='ref-tag'>[@2022-10-25|MR | MR]</div>
<div class='ref-details'>
<div class='ref-detail-line'>MR ID: 2022-10-25|MR | Date: 2022-10-25</div>
<div class='ref-detail-line'>Content: å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”...</div>
</div>
</div>
</div>
</div>
    </div>
    <div class="card">
      <h2>Question (raw)</h2>
      <div class="hint">Original user question for observability (passed from main via args.question_raw).</div>
      <pre>åµå·¢ç™Œï¼šæµè°ƒå¦è®¤ä¸­é«˜é£é™©åœ°åŒºæ—…å±…å²ï¼Œå¦è®¤ä½“æ¸©å¼‚å¸¸ç­‰æ–°å† è‚ºç‚ç—‡çŠ¶ã€‚2021.08.26åœ¨å…¨éº»ä¸‹è¡Œæ‰©å¤§æ€§å…¨å­å®«åˆ‡é™¤æœ¯+åŒé™„ä»¶åˆ‡é™¤æœ¯+ç›†è…”è‚¿å—åˆ‡é™¤æœ¯+ç›´è‚ ä¹™çŠ¶ç»“è‚ éƒ¨åˆ†åˆ‡é™¤æœ¯+ä¹™çŠ¶ç»“è‚ é€ å£æœ¯+å¤§ç½‘è†œåˆ‡é™¤æœ¯+ç›†è…”æ·‹å·´ç»“æ¸…æ‰«æœ¯+é˜‘å°¾åˆ‡é™¤æœ¯+è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“æ¸…æ‰«æœ¯ã€‚æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ .
2021.09.06ã€09.07äºˆé¡ºé“‚50mgè…¹è…”åŒ–ç–—ã€2021.10.18èµ·è¡ŒTPåŒ–ç–—6ç¨‹ï¼Œæœ«æ¬¡åŒ–ç–—2022.3.22æˆ‘é™¢åŸºå› æ£€æµ‹ç»“æœï¼šHRD(+)æœç”¨å°¼æ‹‰å¸•åˆ©1å‘¨ï¼Œè¯‰ååº”å¤§ï¼Œè‡ª2022.4.26å¼€å§‹åœè¯ã€‚2022.4.18è¡€å¸¸è§„ï¼šPLT:33ä»Šæ—¥è¡€å¸¸è§„ï¼šPLT:342022.5.23èµ·æ¢å¤å°¼æ‹‰å¸•åˆ©1#qdã€‚
ç›®å‰ååº”å¯ã€‚2022.6.24è‡³ä¸­å±±åŒ»é™¢è¡Œè…¹å£ç–ä¿®è¡¥æœ¯ã€‚å› æ‰‹æœ¯å°¼æ‹‰å¸•åˆ©åœè¯3å‘¨ã€‚ç›®å‰ç»§ç»­å£æœå°¼æ‹‰å¸•åˆ©ä¸­ã€‚è¯‰æœ€è¿‘è…¹ç—›å‡ æ¬¡ï¼Œè…¹èƒ€æ˜æ˜¾ã€‚CTï¼ˆ2022.09.27ï¼‰ï¼šå³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
CTï¼ˆ2022.10.08ï¼‰ï¼šè‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚å·¦è‚¾å›Šè‚¿åŒå‰ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚
MRï¼ˆ2022.10.25ï¼‰ï¼šåµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚æœ€è¿‘å¤æŸ¥æŠ¥å‘Šå¥½ã€‚2022.12.30ä¸­å±±åŒ»é™¢ï¼šåˆ‡å£ç–ï¼Œè‚å³å¶ä½å¯†åº¦ç¶ã€‚è¡€å¸¸è§„ã€è‚è‚¾åŠŸèƒ½ä¸€èˆ¬å¯; ECOG=1</pre>

      <details class="mt">
        <summary>Case (Structured JSON)</summary>
        <pre>{&quot;CASE_CORE&quot;:{&quot;ADJUVANT_TREATMENT&quot;:{&quot;cycles_or_courses&quot;:&quot;6&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;TP&quot;]},&quot;BIOMARKERS&quot;:{&quot;AFP&quot;:&quot;Unknown&quot;,&quot;CA125&quot;:&quot;Unknown&quot;,&quot;HER2&quot;:&quot;Unknown&quot;,&quot;MSI&quot;:&quot;Unknown&quot;,&quot;PDL1_CPS&quot;:&quot;Unknown&quot;,&quot;TMB&quot;:&quot;Unknown&quot;},&quot;BRCA1&quot;:&quot;Unknown&quot;,&quot;BRCA2&quot;:&quot;Unknown&quot;,&quot;CURRENT_STATUS&quot;:&quot;On maintenance niraparib; ECOG 1; recent imaging without pelvic recurrence.&quot;,&quot;DIAGNOSIS&quot;:{&quot;components&quot;:[&quot;Adenocarcinoma&quot;,&quot;High-grade serous carcinoma&quot;],&quot;histology&quot;:&quot;High-grade serous carcinoma&quot;,&quot;laterality&quot;:&quot;Bilateral&quot;,&quot;primary&quot;:&quot;Ovarian cancer&quot;,&quot;site&quot;:&quot;Ovary&quot;},&quot;ECOG&quot;:&quot;1&quot;,&quot;GENOMICS&quot;:{&quot;HRD_STATUS&quot;:{&quot;method&quot;:&quot;Unknown&quot;,&quot;result&quot;:&quot;Positive&quot;,&quot;score&quot;:&quot;Unknown&quot;},&quot;alterations&quot;:[],&quot;testing_date&quot;:&quot;Unknown&quot;,&quot;testing_performed&quot;:&quot;Yes&quot;,&quot;testing_platform&quot;:&quot;Unknown&quot;},&quot;HRD&quot;:&quot;Positive&quot;,&quot;INITIAL_TREATMENT&quot;:&quot;Yes&quot;,&quot;LINE_OF_THERAPY&quot;:[{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;1&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Switched to TP chemotherapy&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;2021-09-07&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;41&quot;,&quot;regimen&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-09-06&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;6&quot;,&quot;cycles_planned&quot;:&quot;6&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Completed 6 cycles&quot;,&quot;reason&quot;:&quot;Completed&quot;},&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;First_line&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;TP&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2021-10-18&quot;},{&quot;concurrent_bevacizumab&quot;:&quot;No&quot;,&quot;cycles_completed&quot;:&quot;Unknown&quot;,&quot;cycles_planned&quot;:&quot;Unknown&quot;,&quot;discontinuation&quot;:{&quot;detail&quot;:&quot;Temporarily stopped due to adverse reactions and low platelets; restarted 2022-05-23; held 3 weeks around hernia repair; currently continuing&quot;,&quot;reason&quot;:&quot;Other&quot;},&quot;end_date&quot;:&quot;Unknown&quot;,&quot;in_clinical_trial&quot;:&quot;No&quot;,&quot;intent&quot;:&quot;Maintenance&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;pfs_days&quot;:&quot;Unknown&quot;,&quot;regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;response_assessment&quot;:{&quot;best_response&quot;:&quot;Unknown&quot;,&quot;ca125_response&quot;:&quot;Unknown&quot;,&quot;response_criteria&quot;:&quot;Unknown&quot;,&quot;response_date&quot;:&quot;Unknown&quot;},&quot;start_date&quot;:&quot;2022-04-Unknown&quot;}],&quot;MAINTENANCE&quot;:&quot;Yes&quot;,&quot;MAINTENANCE_DETAIL&quot;:{&quot;end_date&quot;:&quot;Unknown&quot;,&quot;given&quot;:&quot;Yes&quot;,&quot;regimens&quot;:[&quot;å°¼æ‹‰å¸•åˆ©&quot;],&quot;start_date&quot;:&quot;2022-04-Unknown&quot;},&quot;NEOADJUVANT&quot;:&quot;Unknown&quot;,&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;PLATINUM_HISTORY&quot;:[{&quot;PFI_days&quot;:&quot;Unknown&quot;,&quot;end_date&quot;:&quot;2022-03-22&quot;,&quot;evidence&quot;:&quot;TP chemotherapy 6 cycles after primary surgery; no explicit relapse documented.&quot;,&quot;evidence_type&quot;:&quot;Unknown&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;line&quot;:&quot;1L&quot;,&quot;start_date&quot;:&quot;2021-10-18&quot;,&quot;status&quot;:&quot;Unknown&quot;}],&quot;PLATINUM_PFI_CURRENT&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS&quot;:&quot;Unknown&quot;,&quot;PLATINUM_STATUS_CURRENT&quot;:&quot;Unknown&quot;,&quot;RELAPSE&quot;:&quot;No&quot;,&quot;RELAPSE_DATE&quot;:{&quot;date&quot;:&quot;Unknown&quot;,&quot;evidence&quot;:&quot;No relapse; pelvic MRI 2022-10-25 showed no abnormal soft tissue in pelvis.&quot;,&quot;type&quot;:&quot;Unknown&quot;},&quot;SCENE&quot;:&quot;Maintenance_surveillance_followup&quot;,&quot;STAGE&quot;:{&quot;stage_basis&quot;:&quot;Unknown&quot;,&quot;stage_system&quot;:&quot;Unknown&quot;,&quot;stage_text&quot;:&quot;Unknown&quot;},&quot;SURGERY_DONE&quot;:{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;performed&quot;:&quot;Yes&quot;,&quot;procedure&quot;:&quot;Radical hysterectomy with bilateral salpingo-oophorectomy, pelvic mass resection, partial rectosigmoid resection, sigmoid colostomy, omentectomy, pelvic lymphadenectomy, appendectomy, paraaortic lymphadenectomy&quot;},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;VISIT_DATE&quot;:&quot;2023-01-09&quot;,&quot;first_relapse_date&quot;:&quot;Unknown&quot;,&quot;last_platinum_end_date&quot;:&quot;2022-03-22&quot;},&quot;CLINICAL_TRIALS&quot;:[],&quot;LAB_TRENDS&quot;:{&quot;labs&quot;:[{&quot;analyte&quot;:&quot;Other&quot;,&quot;history&quot;:[{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;}],&quot;latest&quot;:{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;flag&quot;:&quot;â†“&quot;,&quot;value&quot;:&quot;PLT:33&quot;},&quot;reference_range&quot;:&quot;Unknown&quot;,&quot;unit&quot;:&quot;Unknown&quot;}],&quot;milestones&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary debulking surgery for ovarian cancer&quot;,&quot;type&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoStart&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Completed TP chemotherapy&quot;,&quot;type&quot;:&quot;ChemoEnd&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Thrombocytopenia (PLT 33) on blood routine&quot;,&quot;type&quot;:&quot;Other&quot;}]},&quot;MED_ONC&quot;:{&quot;current_regimen&quot;:{&quot;cycle_info&quot;:&quot;Continuous oral maintenance; temporarily stopped 2022-04-26 and around 2022-06-24 surgery; currently continuing&quot;,&quot;last_admin_date&quot;:&quot;Unknown&quot;,&quot;name&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},&quot;genetic_testing&quot;:{&quot;germline&quot;:[],&quot;somatic&quot;:[&quot;HRD&quot;]},&quot;monitoring_points&quot;:[{&quot;drug_or_class&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;monitoring&quot;:[&quot;Monitor platelet count due to prior thrombocytopenia&quot;]}],&quot;planned_next_regimen&quot;:&quot;Unknown&quot;,&quot;prior_systemic_therapies&quot;:[&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;,&quot;TP&quot;]},&quot;NUC_MED&quot;:{&quot;studies&quot;:[]},&quot;PATHOLOGY&quot;:{&quot;specimens&quot;:[{&quot;components&quot;:[&quot;High-grade serous carcinoma&quot;,&quot;Myometrial leiomyomas&quot;,&quot;Chronic cervicitis&quot;],&quot;date&quot;:&quot;2021-08-26&quot;,&quot;diagnosis&quot;:&quot;Adenocarcinoma consistent with high-grade serous carcinoma&quot;,&quot;grade&quot;:&quot;High-grade&quot;,&quot;ihc&quot;:[],&quot;involvement_sites&quot;:[&quot;Left ovary&quot;,&quot;Right ovary&quot;,&quot;Left fallopian tube&quot;,&quot;Right fallopian tube&quot;,&quot;Uterine myometrium&quot;,&quot;Pelvic and abdominal peritoneum&quot;,&quot;Partial rectosigmoid colon from serosa to superficial muscle&quot;,&quot;Omentum&quot;,&quot;Left paracolic gutter peritoneum&quot;,&quot;Small bowel mesentery&quot;,&quot;Sigmoid mesentery&quot;,&quot;Appendiceal serosa&quot;,&quot;Pelvic lymph nodes&quot;,&quot;Para-aortic and mesenteric lymph nodes (some positive)&quot;],&quot;laterality&quot;:&quot;Bilateral ovarian involvement&quot;,&quot;molecular&quot;:[{&quot;result&quot;:&quot;Positive&quot;,&quot;test&quot;:&quot;HRD&quot;}],&quot;raw_text&quot;:&quot;æœ¯åç—…ç†ï¼šæ ‡æœ¬ç±»å‹:æ‰©å¤§å­å®«+åŒé™„ä»¶+å·¨å¤§ç›†å—+éƒ¨åˆ†ç›´ä¹™ç»“è‚ +ç›†è…¹è…”å¤šç—…ç¶è‚¿ç˜¤å¤§å°:å·¦ä¾§ï¼š3.5Ã—2Ã—1.5cmï¼›å³ä¾§ï¼š6Ã—5.5Ã—4.5cmè‚¿ç˜¤ä¾§åˆ«:åŒä¾§ç—…ç†ç±»å‹:è…ºç™Œï¼Œç»“åˆå…ç–«ç»„åŒ–ç»“æœï¼ˆI2021-07819ï¼‰ï¼Œç¬¦åˆé«˜çº§åˆ«æµ†æ¶²æ€§ç™Œã€‚å…¶ä»–éƒ¨ä½æƒ…å†µ:å·¦è¾“åµç®¡:è§ç™Œç´¯åŠå³è¾“åµç®¡:è§ç™Œç´¯åŠå­å®«å†…è†œ:èç¼©æ”¹å˜å®«é¢ˆ:æ…¢æ€§ç‚å­å®«è‚Œå±‚:è§ç™Œç´¯åŠï¼›è‚Œå£é—´å¹³æ»‘è‚Œç˜¤ï¼ˆå¤šæšï¼Œç›´å¾„0.5-2cmï¼‰ç›†è…¹è…”å¤šéƒ¨ä½ç—…ç¶:ï¼ˆéƒ¨åˆ†ç›´ä¹™ç»“è‚ ï¼‰è§ç™Œç´¯åŠï¼Œè‡ªæµ†è†œå±‚æµ¸æ¶¦è‡³æµ…è‚Œå±‚ï¼Œè‚ ç®¡ä¸¤åˆ‡ç¼˜æœªè§ç™Œç´¯åŠã€‚ï¼ˆå¤§ç½‘è†œã€å¤§ç½‘è†œåŠç›†è…”è‚¿å—ã€å·¦ä¾§ç»“è‚ æ—æ²Ÿè…¹è†œã€å°è‚ ç³»è†œè‚¿ç˜¤ã€ä¹™çŠ¶ç»“è‚ ç³»è†œè‚¿ç˜¤ï¼‰è§ç™Œç´¯åŠ.ï¼ˆé˜‘å°¾åŠå‘¨å›´è‚¿å—ï¼‰ æµ†è†œå±‚è§ç™Œç´¯åŠã€‚å…¶ä»–:é€æ£€æ·‹å·´ç»“ï¼ˆ6/24ï¼‰è§ç™Œè½¬ç§»ï¼Œå…¶ä¸­ï¼šå·¦ç›†è…”æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼›å³ç›†è…”æ·‹å·´ç»“ï¼ˆ3/8ï¼‰ï¼›è…¹ä¸»è‚ ç³»è†œä¸‹æ–¹æ·‹å·´ç»“ï¼ˆ1/4ï¼‰ï¼› è‚ ç³»è†œä¸‹åŠ¨è„‰ä¸Šæ–¹æ·‹å·´ç»“ï¼ˆ1/2ï¼‰ï¼›è…¹ä¸»åŠ¨è„‰æ—æ·‹å·´ç»“ï¼ˆ0/6ï¼‰ã€‚&quot;,&quot;sample_type&quot;:&quot;Surgical resection&quot;,&quot;site&quot;:&quot;Uterus, bilateral adnexa, pelvic mass, rectosigmoid colon, peritoneum, omentum, appendix, lymph nodes&quot;,&quot;tumor_size&quot;:&quot;Left ovary 3.5Ã—2Ã—1.5cm; right ovary 6Ã—5.5Ã—4.5cm&quot;,&quot;uncertainty_or_missing&quot;:[&quot;FIGO stage not provided&quot;,&quot;IHC panel details not provided&quot;]}]},&quot;RADIOLOGY&quot;:{&quot;next_imaging_plan&quot;:{&quot;modality&quot;:&quot;Unknown&quot;,&quot;timing&quot;:&quot;Unknown&quot;},&quot;studies&quot;:[{&quot;anatomic_sites&quot;:[&quot;Lung&quot;,&quot;Pleura&quot;,&quot;Chest&quot;],&quot;date&quot;:&quot;2022-09-27&quot;,&quot;findings&quot;:[&quot;Right upper lung arteriovenous fistula similar to prior&quot;,&quot;Right upper lung apical segment small nodule similar to prior&quot;,&quot;Left upper lung scattered tiny nodules&quot;,&quot;Small bilateral pleural effusions decreased compared with prior&quot;,&quot;Scattered chronic inflammatory and fibrotic changes in lungs&quot;,&quot;Atelectasis improved&quot;,&quot;Nodule at right cardiophrenic angle less apparent&quot;],&quot;impression&quot;:&quot;Pulmonary AV fistula and nodules unchanged; pleural effusions and atelectasis improved&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Improved&quot;},{&quot;anatomic_sites&quot;:[&quot;Liver&quot;,&quot;Kidney&quot;,&quot;Spine&quot;],&quot;date&quot;:&quot;2022-10-08&quot;,&quot;findings&quot;:[&quot;Hemangioma in liver right lobe segment VII similar to prior&quot;,&quot;Left renal cyst similar to prior&quot;,&quot;Localized uneven sclerotic change in lumbar vertebrae similar to prior&quot;],&quot;impression&quot;:&quot;Stable hemangioma and renal cyst; spinal sclerosis unchanged; chest findings to correlate with other exams&quot;,&quot;modality&quot;:&quot;CT&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;},{&quot;anatomic_sites&quot;:[&quot;Pelvis&quot;],&quot;date&quot;:&quot;2022-10-25&quot;,&quot;findings&quot;:[&quot;Postoperative changes after ovarian cancer surgery&quot;,&quot;No abnormal soft tissue mass in pelvis&quot;],&quot;impression&quot;:&quot;No pelvic recurrence; follow-up recommended&quot;,&quot;modality&quot;:&quot;MRI&quot;,&quot;trend_vs_prior&quot;:&quot;Stable&quot;}]},&quot;TIMELINE&quot;:{&quot;constraints&quot;:{&quot;max_events&quot;:30,&quot;min_events&quot;:3,&quot;must_include&quot;:[&quot;first diagnostic imaging or pathology confirmation (if available)&quot;],&quot;ordering_rules&quot;:{&quot;prioritize_last_event&quot;:true}},&quot;events&quot;:[{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Primary cytoreductive surgery including radical hysterectomy, bilateral salpingo-oophorectomy, bowel resection, omentectomy, lymphadenectomy, colostomy, appendectomy&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Multiple peritoneal sites and 6/24 lymph nodes positive for carcinoma&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2021-08-26&quot;,&quot;description&quot;:&quot;Pathology confirmed high-grade serous carcinoma of bilateral ovaries with widespread peritoneal involvement and nodal metastases&quot;,&quot;event_type&quot;:&quot;Diagnosis&quot;,&quot;key_result&quot;:&quot;High-grade serous carcinoma, bilateral ovaries; 6/24 lymph nodes positive&quot;,&quot;regimen_or_test&quot;:&quot;Pathology&quot;},{&quot;date&quot;:&quot;2021-09-06&quot;,&quot;description&quot;:&quot;Intraperitoneal chemotherapy with cisplatin 50mg&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed over 2021-09-06 and 2021-09-07&quot;,&quot;regimen_or_test&quot;:&quot;é¡ºé“‚50mgè…¹è…”åŒ–ç–—&quot;},{&quot;date&quot;:&quot;2021-10-18&quot;,&quot;description&quot;:&quot;Started TP chemotherapy, planned 6 cycles&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Completed 6 cycles, last on 2022-03-22&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-03-22&quot;,&quot;description&quot;:&quot;Last cycle of TP chemotherapy&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Adjuvant chemotherapy completed&quot;,&quot;regimen_or_test&quot;:&quot;TP&quot;},{&quot;date&quot;:&quot;2022-04-18&quot;,&quot;description&quot;:&quot;Complete blood count showing thrombocytopenia&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:33&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;},{&quot;date&quot;:&quot;2022-04-26&quot;,&quot;description&quot;:&quot;Stopped niraparib due to strong adverse reactions&quot;,&quot;event_type&quot;:&quot;Other&quot;,&quot;key_result&quot;:&quot;Maintenance paused&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-05-23&quot;,&quot;description&quot;:&quot;Restarted niraparib 1# qd&quot;,&quot;event_type&quot;:&quot;Chemo&quot;,&quot;key_result&quot;:&quot;Maintenance resumed&quot;,&quot;regimen_or_test&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;},{&quot;date&quot;:&quot;2022-06-24&quot;,&quot;description&quot;:&quot;Abdominal wall hernia repair at Zhongshan Hospital&quot;,&quot;event_type&quot;:&quot;Surgery&quot;,&quot;key_result&quot;:&quot;Niraparib held for 3 weeks around surgery&quot;,&quot;regimen_or_test&quot;:&quot;Surgery&quot;},{&quot;date&quot;:&quot;2022-09-27&quot;,&quot;description&quot;:&quot;CT chest/abdomen showing small bilateral pleural effusions improved; pulmonary AV fistula and nodules similar to prior&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new malignant findings reported; abdominal details deferred&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-08&quot;,&quot;description&quot;:&quot;CT showing liver segment VII hemangioma and left renal cyst, stable&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No new findings; chest to correlate with other exams&quot;,&quot;regimen_or_test&quot;:&quot;CT&quot;},{&quot;date&quot;:&quot;2022-10-25&quot;,&quot;description&quot;:&quot;Pelvic MRI after ovarian cancer surgery&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;No abnormal soft tissue in pelvis; follow-up recommended&quot;,&quot;regimen_or_test&quot;:&quot;MR&quot;},{&quot;date&quot;:&quot;2022-12-30&quot;,&quot;description&quot;:&quot;Zhongshan Hospital evaluation: incisional hernia, low-density lesion in right liver lobe&quot;,&quot;event_type&quot;:&quot;Imaging&quot;,&quot;key_result&quot;:&quot;Blood count and liver/kidney function generally acceptable&quot;,&quot;regimen_or_test&quot;:&quot;Imaging&quot;},{&quot;date&quot;:&quot;2023-01-09&quot;,&quot;description&quot;:&quot;Recent blood routine showed platelet count 34 (year not fully specified)&quot;,&quot;event_type&quot;:&quot;Lab&quot;,&quot;key_result&quot;:&quot;PLT:34 (interpreted from &#x27;PLT:342022.5.23èµ·æ¢å¤&#x27;, year unclear)&quot;,&quot;regimen_or_test&quot;:&quot;Blood routine&quot;}]},&quot;TOXICITIES&quot;:[{&quot;attribution&quot;:&quot;Probable&quot;,&quot;dose_modification&quot;:&quot;Yes&quot;,&quot;onset_date&quot;:&quot;2022-04-18&quot;,&quot;outcome&quot;:&quot;Resolved&quot;,&quot;related_line&quot;:&quot;1L&quot;,&quot;related_regimen&quot;:&quot;å°¼æ‹‰å¸•åˆ©&quot;,&quot;severity&quot;:&quot;Severe&quot;,&quot;toxicity&quot;:&quot;Strong adverse reaction to niraparib with thrombocytopenia (PLT 33)&quot;}]}</pre>
      </details>
    </div>
  </div>

  <details class="mt" open>
    <summary>Clinical Trial Recommendation</summary>
    <pre>Trial Recommendation:
- id: None
- name: None
- Reason: Disease setting/line and required biomarkers for available trials are not clearly met based on the case.
- Missing eligibility confirmations (0-2 items):
  - HER2 / TF / EGFR/HER3 / HPV16 status and other trial-specific biomarkers
  - Clear documentation of recurrent/metastatic or unresectable disease and prior systemic therapy lines in the advanced setting</pre>
    <div class="hint">Shown only when the trial matcher produced a recommendation.</div>
  </details>

  <details class="mt" open>
    <summary>ğŸ“‹ MDT Discussion Summary (Assistant)</summary>
    <pre>Key Knowledge:
- Disseminated high-grade serous carcinoma, HRD-positive and BRCA-wildtype on NGS, on first-line PARP inhibitor maintenance after platinum response.  
- Prior thrombocytopenia has resolved; current blood counts, organ function, and CA125/HE4 are acceptable for continued PARP maintenance.  
- Cross-sectional imaging (CT chest/abdomen and pelvic MRI up to 2022-10-25) shows no pelvic recurrence, no ascites/adenopathy, and only stable benign-appearing lesions (liver hemangioma, renal cyst, lumbar sclerosis, small pulmonary nodules, AV fistula).  
- PARP maintenance in HRD-positive disease is guideline-supported and intended as finite therapy, generally over 2â€“3 years, with regular toxicity and hematologic monitoring.  
- Current surveillance strategy is morphology-based (CT/MR) with serial CA125Â±HE4.

Controversies:
- Exact optimal total duration of PARP maintenance within the 2â€“3-year window for this individual patient.  
- Role and timing of FDG PET/CT in an asymptomatic patient in radiologic remission, given guidelines favor reserving PET/CT for biochemical rise or equivocal CT/MR.

Missing Info:
- Confirmed FIGO stage at diagnosis.  
- Full original pathology/IHC report (I2021-07819) and integrated final pathology summary including HRD/NGS findings.  
- Updated imaging beyond 2022-10-25 to confirm ongoing remission.  
- Longitudinal CA125/HE4 trends and any interval clinical symptoms or PARP-related toxicities.  
- No prior FDG PET/CT; metabolic staging and assessment for occult disease remain incomplete (to be done only if triggered).

Working Plan:
- Continue current first-line PARP inhibitor maintenance toward a finite 2â€“3-year duration, with close hematologic, organ-function, and toxicity monitoring.  
- Implement structured surveillance: CA125Â±HE4 at each visit and updated contrast-enhanced CT chest/abdomen plus pelvic MRI now, then at guideline-consistent intervals or earlier if markers/symptoms change.  
- Retrieve and document complete pathology/IHC report and confirm FIGO stage; integrate HRD-positive, BRCA-wildtype NGS results into the final pathology/staging summary.  
- Reserve FDG PET/CT for rising CA125/HE4, new concerning symptoms, or equivocal/new lesions on CT/MR, to reassess nodal/peritoneal and extra-pelvic disease if triggered.</pre>
    <div class="hint">Structured summary of Key Knowledge, Controversies, Missing Info, and Working Plan.</div>
  </details>

  <details class="mt" open>
    <summary>Expert Debate (Round Ã— Turn)</summary>
    <table class='grid'><tr><th>Round</th><th>Turn</th><th>From</th><th>To</th><th>Message</th></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>oncologist</td><td>Before finalizing duration and intensity of ongoing PARP maintenance, we must document FIGO stage, full pathology/IHC (I2021-07819), updated CA125/HE4 trends and imaging after 2022-10-25, and interval toxicities/symptoms; current markers and blood counts are acceptable [@20230109|9701878 | LAB] [@20230109|5600622 | LAB], but guideline-based duration remains flexible in HRD-positive, BRCA-wildtype disease [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>radiologist</td><td>We need a concrete surveillance plan (modality and interval) and updated cross-sectional imaging after 2022-10-25 to confirm continued non-recurrence [@2022-10-25|MR | MR].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>chair</td><td class='mono'>nuclear</td><td>Please advise whether FDG PET/CT adds value in this asymptomatic HRD-positive patient without clear CT/MR recurrence, and define triggers (marker rise/equivocal lesions) for PET use [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15].</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>oncologist</td><td class='mono'>chair</td><td>For regimen decisions, I still lack confirmed FIGO stage and full pathology/IHC (report I2021-07819), plus updated imaging and CA125 trend after 2022-10-25 and 2023-01-09 labs, which are critical to justify ongoing first-line maintenance versus later surveillance-only strategy. [@20230109|5600622 | LAB] [@20230109|9701878 | LAB]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>radiologist</td><td class='mono'>oncologist</td><td>From an imaging standpoint, we lack any cross-sectional studies after 2022-10-25 to confirm continued radiologic remission; updated CT chest/abdomen and pelvic MRI are needed to align with the current visit. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>pathologist</td><td class='mono'>chair</td><td>FIGO stage and full IHC profile (report I2021-07819) remain undocumented; definitive staging and biomarker summary are critical for accurate record and future decision-making. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]</td></tr><tr><td class='mono'>Round 1</td><td class='mono'>Turn 1</td><td class='mono'>nuclear</td><td class='mono'>radiologist</td><td>From a metabolic standpoint, there is still no FDG PET/CT for this high-grade serous case; occult nodal or extra-pelvic disease cannot be excluded on morphology alone, so a baseline PET/CT would meaningfully refine current staging if tumor markers or future CT/MR become equivocal. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]</td></tr></table>
    <div class="hint">Only includes messages that were actually emitted (non-empty).</div>
  </details>

  <details class="mt">
    <summary>Initial Expert Opinions (raw)</summary>
    <pre>{
  &quot;chair&quot;: &quot;- Continue current PARP maintenance with close platelet monitoring; counts currently normal at PLT 145 and organ function acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB].  \n\n- Maintain surveillance: periodic CA125/HE4 and crossâ€‘sectional imaging; no pelvic recurrence on MRI 2022-10-25 [@2022-10-25|MR | MR] [@20230109|9701878 | LAB].  \n\n- Firstâ€‘line PARP maintenance in HRDâ€‘positive, postâ€‘platinum responders is guidelineâ€‘supported; duration typically finite (2â€“3 years) [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8].&quot;,
  &quot;oncologist&quot;: &quot;- Currently on first-line PARP-inhibitor maintenance with no radiologic recurrence; continue maintenance with close toxicity and hematologic monitoring. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Platelets and organ function now adequate for ongoing maintenance; prior thrombocytopenia has resolved. [@20230109|5600622 | LAB] [@20230109|8300382 | LAB]\n\n- Need updated cross-sectional imaging report and CA125 trend beyond 2022-10-25 to better define response and surveillance plan.&quot;,
  &quot;radiologist&quot;: &quot;- No measurable pelvic recurrence or mass; postoperative pelvis remains clear of disease on MRI. [@2022-10-25|MR | MR] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Chest CT shows stable small pulmonary nodules and AV fistula; prior pleural effusions and atelectasis have improved. [@2022-09-27|CT | CT]\n\n- Abdominal CT demonstrates stable benign-appearing liver hemangioma, left renal cyst, and lumbar sclerosis; no ascites or adenopathy. [@2022-09-29|CT | CT]&quot;,
  &quot;pathologist&quot;: &quot;- Diagnosis: disseminated high-grade serous carcinoma involving bilateral adnexa, uterus, bowel serosa/muscle, peritoneum, nodes; FIGO stage needs confirmation. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 4]\n\n- HRD positive on comprehensive NGS; no pathogenic BRCA1/2, TP53, ARID1A, PTEN, PIK3CA, PALB2, RAD51D, BRIP1, BARD1 variants. [@OH2201222 | Genomics]\n\n- Missing/uncertain: full original IHC panel report (I2021-07819), FIGO stage assignment, CA125 and other serum tumor markers. Unknown/needs update.&quot;,
  &quot;nuclear&quot;: &quot;- No PET/FDG study is available; metabolic staging and assessment of recurrence risk are currently impossibleâ€”PET/CT acquisition is needed.  \n\n- Prior CT and pelvic MR show no evident pelvic recurrence; PET could upstage by revealing extra-pelvic hypermetabolic disease. [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]  \n\n- In ovarian cancer, FDG PET/CT improves detection of nodal and distant metastases and suspected recurrence over morphology alone. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]&quot;
}</pre>
  </details>

  <details class="mt">
    <summary>Final Refined Plans (per round, raw)</summary>
    <pre>{
  &quot;Round 1&quot;: {
    &quot;chair&quot;: &quot;- Continue current PARP maintenance with close hematologic/organ monitoring; counts and CA125/HE4 currently acceptable [@20230109|5600622 | LAB] [@20230109|8300382 | LAB] [@20230109|9701878 | LAB].  \n\n- Implement surveillance: serial markers (CA125Â±HE4) and scheduled CT chest/abdomen plus pelvic MRI; obtain updated imaging beyond 2022-10-25 [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR].  \n\n- Before altering maintenance duration, complete FIGO staging and full IHC report, and consider PET/CT only if markers rise or CT/MR equivocal [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12].&quot;,
    &quot;oncologist&quot;: &quot;- Continue first-line PARP-inhibitor maintenance toward a finite 2â€“3â€‘year total duration, with regular toxicity and blood-count monitoring. [@20230109|5600622 | LAB] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Implement surveillance with CA125Â±HE4 every visit and CT chest/abdomen plus pelvic MRI approximately annually, or sooner if markers/symptoms change. [@20230109|9701878 | LAB] [@2022-10-25|MR | MR]\n\n- Obtain complete pathology/IHC and FIGO stage (I2021-07819); reserve FDG PET/CT for rising markers or equivocal CT/MR findings. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]&quot;,
    &quot;radiologist&quot;: &quot;- Obtain updated contrast-enhanced CT chest/abdomen and pelvic MRI now to confirm ongoing radiologic remission and guide surveillance intervals. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]\n\n- If future CT/MR shows equivocal lesions or tumor markers rise, add FDG PET/CT to assess occult nodal/extra-pelvic disease. [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]\n\n- Pending new imaging, continue morphology-based surveillance with CT/MR at guideline-consistent intervals; no current evidence of measurable recurrence radiologically. [@2022-09-27|CT | CT] [@2022-09-29|CT | CT] [@2022-10-25|MR | MR]&quot;,
    &quot;pathologist&quot;: &quot;- Confirm and document FIGO stage plus full pathology/IHC report I2021-07819 for definitive staging and biomarker profile. [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 3]\n\n- Ensure HRD-positive, BRCA-wildtype molecular summary from NGS (including negative BRCA1/2 and other genes) is clearly integrated into the pathology report. [@OH2201222 | Genomics]\n\n- Pathology file should explicitly correlate disseminated high-grade serous carcinoma distribution with final stage once imaging and clinical data are updated.&quot;,
    &quot;nuclear&quot;: &quot;- Reserve FDG PET/CT for rising CA125/HE4, new symptoms, or equivocal/new lesions on follow-up CT/MR. [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]  \n\n- When triggered, PET/CT should specifically reassess nodal basins, peritoneum, and extra-pelvic sites to upstage or confirm remission.  \n\n- Until a trigger occurs, continue morphology-based surveillance; metabolic staging remains incomplete due to absence of prior PET/CT (unknown/needs update).&quot;
  }
}</pre>
  </details>

  <details class="mt" open>
    <summary>Selected Clinical Context</summary>
    <table class='grid'><tr><th>Role</th><th>Lab (n)</th><th>Lab newest</th><th>Imaging (n)</th><th>Imaging newest</th><th>Pathology (n)</th><th>Pathology newest</th><th>Mutation (n)</th><th>Mutation newest</th></tr><tr><td class='mono'>chair</td><td>3</td><td>2023-01-09</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>nuclear</td><td>0</td><td>-</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>0</td><td>-</td></tr><tr><td class='mono'>oncologist</td><td>3</td><td>2023-01-09</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>pathologist</td><td>0</td><td>-</td><td>0</td><td>-</td><td>0</td><td>-</td><td>1</td><td>2022-01-24</td></tr><tr><td class='mono'>radiologist</td><td>0</td><td>-</td><td>3</td><td>2022-10-25</td><td>0</td><td>-</td><td>0</td><td>-</td></tr></table>
    <div class="hint">Counts and newest dates per role/report type (including mutation).</div>
    <details class="mt">
      <summary>Raw Context (JSON)</summary>
      <pre>{
  &quot;lab&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;20230109|5600622&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 10 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 1.00 % (BASO)\næ·‹å·´ç»†èƒ% 28.8 % (LYM)\nå•æ ¸ç»†èƒ% 7.5 % (MID)\nå—œé…¸æ€§ç»†èƒæ•° 0.04 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.70 % (EOS)\nå¹³å‡PLTå®¹ç§¯ 9.4 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 2.18 nan (NL)\nçº¢ç»†èƒè®¡æ•° 3.96 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 145 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 11.8 % (RDWCV)\nçº¢ç»†èƒæ¯”ç§¯ 37.7 % (HCT)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 31.6 pg (MCH)\næ·‹å·´ç»†èƒæ•° 1.7 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 3.7 *10^9/L (GRAN#)\nç™½ç»†èƒè®¡æ•° 6.0 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 125 g/l (HGB)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 95.2 fl (MCV)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— ACCEPT nan (VFLAG)\nå•æ ¸ç»†èƒæ•° 0.5 *10^9/L (MID#)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 332.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.14 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 41 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|8300382&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT)\nå°¿ç´  4.65 mmol/l (UREA)\nä¹³é…¸è„±æ°¢é…¶ 267 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.1 U/l (ALT)\nè‚Œé… 68 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.87 nan (A/G)\nç¢±æ€§ç£·é…¸é…¶ 96.3 U/L (ALP)\nå‰ç™½è›‹ç™½ 234 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  5.0 umol/L (IBIL)\næ€»èƒ†çº¢ç´  9.6 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 2.4 U/L (GLDH)\nç›´æ¥èƒ†çº¢ç´  4.6 umol/l (DBIL)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.68 mmol/L (NEFA)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.5 U/L (AST)\nå°¿é…¸ 242 umol/l (UA)\nç™½è›‹ç™½ 45.7 g/l (ALB)\næ€»è›‹ç™½ 70.1 g/l (TP)\nè°·è‰åŒå·¥é…¶ 8.3 U/L (ASTM)\nçƒè›‹ç™½ 24.4 g/l (GELO)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|9701878&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125)\näººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 18.17 %(ç»ç»å‰) (ROMA)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 10.06 %(ç»ç»å) (ROMA.)&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;20230109|5600622&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ä¸­æ€§ç²’ç»†èƒ% 62.0 % (GRAN)\nPLTåˆ†å¸ƒå®½åº¦ 10 % (PDW)\nå—œç¢±æ€§ç»†èƒæ•° 0.06 *10^9/L (BASO#)\nå—œç¢±æ€§ç»†èƒ% 1.00 % (BASO)\næ·‹å·´ç»†èƒ% 28.8 % (LYM)\nå•æ ¸ç»†èƒ% 7.5 % (MID)\nå—œé…¸æ€§ç»†èƒæ•° 0.04 *10^9/L (EOS#)\nå—œé…¸æ€§ç»†èƒ% 0.70 % (EOS)\nå¹³å‡PLTå®¹ç§¯ 9.4 fl (MPV)\nä¸­æ€§æ·‹å·´æ¯”å€¼ 2.18 nan (NL)\nçº¢ç»†èƒè®¡æ•° 3.96 *10^12/L (RBC)\nè¡€å°æ¿è®¡æ•° 145 *10^9/L (PLT)\nRBCåˆ†å¸ƒå®½åº¦-CV 11.8 % (RDWCV)\nçº¢ç»†èƒæ¯”ç§¯ 37.7 % (HCT)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½é‡ 31.6 pg (MCH)\næ·‹å·´ç»†èƒæ•° 1.7 *10^9/L (LYM#)\nä¸­æ€§ç²’ç»†èƒæ•° 3.7 *10^9/L (GRAN#)\nç™½ç»†èƒè®¡æ•° 6.0 *10^9/L (WBC)\nè¡€çº¢è›‹ç™½é‡ 125 g/l (HGB)\nå¹³å‡çº¢ç»†èƒä½“ç§¯ 95.2 fl (MCV)\nè‡ªåŠ¨å®¡æ ¸æ ‡å¿— ACCEPT nan (VFLAG)\nå•æ ¸ç»†èƒæ•° 0.5 *10^9/L (MID#)\nå¹³å‡çº¢ç»†èƒè¡€çº¢è›‹ç™½æµ“åº¦ 332.0 g/l (MCHC)\nè¡€å°æ¿å‹ç§¯ 0.14 % (PCT)\nRBCåˆ†å¸ƒå®½åº¦-SD 41 nan (RDWSD)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|8300382&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;Î³-è°·æ°¨é…°åŸºè½¬ç§»é…¶ 24 U/L (GGT)\nå°¿ç´  4.65 mmol/l (UREA)\nä¹³é…¸è„±æ°¢é…¶ 267 U/L (LDH)\nä¸™æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.1 U/l (ALT)\nè‚Œé… 68 umol/l (CRE)\nç™½çƒæ¯”ä¾‹ 1.87 nan (A/G)\nç¢±æ€§ç£·é…¸é…¶ 96.3 U/L (ALP)\nå‰ç™½è›‹ç™½ 234 mg/L (PA)\né—´æ¥èƒ†çº¢ç´  5.0 umol/L (IBIL)\næ€»èƒ†çº¢ç´  9.6 umol/l (TBIL)\nè°·æ°¨é…¸è„±æ°¢é…¶ 2.4 U/L (GLDH)\nç›´æ¥èƒ†çº¢ç´  4.6 umol/l (DBIL)\næ¸¸ç¦»è„‚è‚ªé…¸ 0.68 mmol/L (NEFA)\nå¤©å†¬æ°¨é…¸æ°¨åŸºè½¬ç§»é…¶ 14.5 U/L (AST)\nå°¿é…¸ 242 umol/l (UA)\nç™½è›‹ç™½ 45.7 g/l (ALB)\næ€»è›‹ç™½ 70.1 g/l (TP)\nè°·è‰åŒå·¥é…¶ 8.3 U/L (ASTM)\nçƒè›‹ç™½ 24.4 g/l (GELO)&quot;
      },
      {
        &quot;report_id&quot;: &quot;20230109|9701878&quot;,
        &quot;date&quot;: &quot;2023-01-09T00:00:00&quot;,
        &quot;raw_text&quot;: &quot;ç³–é“¾æŠ—åŸ125 6.45 U/ml (CA125)\näººé™„ç¾è›‹ç™½4 78.30 pmol/L (HE4)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼ 18.17 %(ç»ç»å‰) (ROMA)\nåµå·¢æ¶æ€§è‚¿ç˜¤é£é™©å€¼. 10.06 %(ç»ç»å) (ROMA.)&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;imaging&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: [
      {
        &quot;report_id&quot;: &quot;2022-09-27|CT&quot;,
        &quot;date&quot;: &quot;2022-09-27T13:15:38&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”å‰ç‰‡2021-09-01ï¼šå³ä¸Šè‚ºåŠ¨è„‰åˆ†æ”¯è¿œç«¯å¢ç²—ä¸”ä¸å³ä¸Šè‚ºé™è„‰åˆ†æ”¯ç›¸é€šï¼Œå³ä¸Šè‚ºé™è„‰åˆ†æ”¯å¢ç²—ï¼ŒåŒå‰ã€‚å³è‚ºå°–æ®µè§å°ç»“èŠ‚åŒå‰ï¼ˆSE206-57ï¼‰ï¼Œçº¦4mmï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°ç»“èŠ‚ï¼Œå°äº3mmï¼›ä¸¤è‚ºå¶æ•£åœ¨å°æ–‘ç‰‡æ¡ç´¢çŠ¶é«˜å¯†åº¦å½±ï¼›æ°”ç®¡å±…ä¸­ï¼Œæ‰€è§å„æ”¯æ°”ç®¡è…”é€šç•…ï¼Œå¿ƒå½±å¤§å°æ­£å¸¸ï¼Œçºµéš”æœªè§æ˜æ˜¾è‚¿å¤§æ·‹å·´ç»“ã€‚èƒ¸è†œæ— å¢åšï¼Œä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ã€‚å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚å½±è¾ƒå‰ä¸æ˜¾ç¤ºã€‚ é™„è§ç”²çŠ¶è…ºä½å¯†åº¦ç»“èŠ‚å½±ã€è‚è„è§ç¨ä½å¯†åº¦ç»“èŠ‚ã€‚ å³ä¸Šè‚ºåŠ¨é™è„‰ç˜˜å¯èƒ½åŒå‰ï¼Œè¯·ç»“åˆä¸´åºŠåŠä¸“é¡¹æ£€æŸ¥ã€‚ å³ä¸Šè‚ºå°–æ®µå°ç»“èŠ‚åŒå‰ï¼Œå·¦ä¸Šè‚ºæ•£åœ¨å°å¾®å°ç»“èŠ‚ï¼Œéšè®¿ã€‚ ä¸¤ä¾§èƒ¸è…”å†…å°‘é‡ç§¯æ¶²è¾ƒå‰å¸æ”¶ï¼›åŒè‚ºæ•£åœ¨æ…¢æ€§ç‚ç—‡åŠçº¤ç»´ï¼Œè‚ºå¶ä¸å¼ è¾ƒå‰å¥½è½¬ã€‚ å³ä¾§å¿ƒè†ˆè§’å¤„ç»“èŠ‚è¾ƒå‰ä¸æ˜æ˜¾ã€‚ ç”²çŠ¶è…ºåŠè…¹éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-09-29|CT&quot;,
        &quot;date&quot;: &quot;2022-09-29T21:44:24&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-09-01ï¼šå·¦ä¸‹è…¹é€ ç˜˜å½±ï¼Œè‚å³å¶VIIæ®µç»“èŠ‚è¾ƒå‰ç›¸ä»¿ï¼Œè¾¹ç¼˜ç»“èŠ‚æ ·å¼ºåŒ–ã€‚è‚å†…å¤–èƒ†ç®¡æ— æ‰©å¼ ï¼Œè„¾ã€èƒ†å›Šã€èƒ°è…ºå¤§å°å½¢æ€åŠå¯†åº¦æ­£å¸¸ï¼ŒåŒä¾§è‚¾è„å¯¹ç§°ï¼Œå¤§å°åŠå½¢æ€æ­£å¸¸ï¼Œå·¦è‚¾è§å›Šæ€§ç»“èŠ‚åŒå‰ã€‚åŒä¾§è‚¾ä¸Šè…ºç»“èŠ‚çŠ¶å¢ç²—ã€‚è…¹è†œåæœªè§è‚¿å¤§æ·‹å·´ç»“ï¼Œè…¹è…”å†…æœªè§ç§¯æ¶²ã€‚æ¨ªè†ˆå‰å¼ºåŒ–æ·‹å·´ç»“è¾ƒå‰ä¸æ˜æ˜¾ã€‚è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ã€‚ è‚å³å¶VIIæ®µè¡€ç®¡ç˜¤åŒå‰ã€‚ å·¦è‚¾å›Šè‚¿åŒå‰ã€‚ è…°æ¤å±€éƒ¨éª¨è´¨ä¸å‡åŒ€è‡´å¯†åŒå‰ï¼Œéšè®¿ã€‚ èƒ¸éƒ¨æƒ…å†µè¯·ç»“åˆç›¸å…³æ£€æŸ¥ã€‚&quot;
      },
      {
        &quot;report_id&quot;: &quot;2022-10-25|MR&quot;,
        &quot;date&quot;: &quot;2022-10-25T13:16:31&quot;,
        &quot;raw_text&quot;: &quot;å¯¹æ¯”2021-8-17ï¼šåµå·¢ç™Œæœ¯åï¼Œé˜´é“æ®‹ç«¯æœªè§æ˜æ˜¾å¢åšï¼Œç›†è…”æœªè§æ˜æ˜¾å¼‚å¸¸ä¿¡å·è‚¿å—ï¼Œç›†ç»„åŠè…¹è‚¡æ²Ÿæ·‹å·´ç»“æœªè§æ˜æ˜¾è‚¿å¤§ï¼Œç›†è…”æœªè§æ˜æ˜¾ç§¯æ¶²ã€‚ åµå·¢ç™Œæœ¯åï¼Œç›®å‰ç›†è…”æœªè§å¼‚å¸¸è½¯ç»„ç»‡å½±ï¼Œè¯·éšè®¿ã€‚&quot;
      }
    ]
  },
  &quot;pathology&quot;: {
    &quot;chair&quot;: [],
    &quot;oncologist&quot;: [],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [],
    &quot;nuclear&quot;: []
  },
  &quot;mutation&quot;: {
    &quot;chair&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;oncologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;radiologist&quot;: [],
    &quot;pathologist&quot;: [
      {
        &quot;report_id&quot;: &quot;OH2201222&quot;,
        &quot;date&quot;: &quot;2022-01-24T13:59:34&quot;,
        &quot;raw_text&quot;: &quot;HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
      }
    ],
    &quot;nuclear&quot;: []
  }
}</pre>
    </details>
  </details>

  <details class="mt">
    <summary>Guideline + PubMed RAG</summary>
    <h3>RAG Query</h3>
    <pre>High-grade serous ovarian carcinoma, platinum-sensitive, with peritoneal and nodal metastases (6/24 nodes); HRD-positive, BRCA1/2-negative on NGS; prior niraparib maintenance limited by severe thrombocytopenia but organ function otherwise acceptable; histology: High-grade serous carcinoma</pre>
    <h3>Evidence Pack (top-k)</h3>
    <pre># GUIDELINE RAG
RAG Evidence Pack (top=5):
[1] score=0.6451 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 8] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]
    MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil- ity of molecular Targets (ESCAT) score: I-A], niraparib for 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or olaparibebevacizumab for 2 years [ESMO- MCBS v1.1 score: 3; ESCAT score: I-A]. o For BRCA1/2-wt/HRD-positive: niraparib for 3 yeaâ€¦
[2] score=0.6450 esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 [PAGE 10] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]
    platinum-based ChT followed by niraparib or rucaparib if in CR/PR/NED [I, B]. Consensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36 voters) Recommendation 13.9: When used as maintenance in patients in CR/PR/NED to platinum-based ChT, olaparib (alone or in combination with bevacizumab) and rucaparibâ€¦
[3] score=0.6438 nccn_ovariancancer_v3_2025__v00000000 [PAGE 12] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]
    Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN. Note: All recommendations are category 2A unless otherwise indicated. NCCN Guiâ€¦
[4] score=0.6400 esmo_cpg_epithelialovarian_2023__v00000000 [PAGE 7] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 7]
    A descriptive OS analysis of SOLO1 at 7-year follow-up60 and the ï¬nal OS analysis of PAOLA-161 have shown a beneï¬t in OS for olaparib in patients with BRCA1/2-mutated tu- mours and olaparibebevacizumab in patients with HRD- positive tumours regardless of BRCA1/2-mut status (see Supplementary Materiaâ€¦
[5] score=0.6294 nccn_ovariancancer_v3_2025__v00000000 [PAGE 15] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]
    based chemotherapy,n preferred for first recurrence (category 1) or Recurrence therapyn,kk and/or Best supportive care (See NCCN Guidelines for Palliative Care) Consider secondary cytoreductive surgeryj,k Immediate platinum-based recurrence therapyn (category 2B) and/or Best supportive care (See NCCâ€¦

# PUBMED RAG
PUBMED Evidence Pack (top=5):
[1] score=0.7352 PMID 35359396 [@pubmed | 35359396]
    Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of
    Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niâ€¦
[2] score=0.7173 PMID 34938651 [@pubmed | 34938651]
    Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.
    Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treâ€¦
[3] score=0.7119 PMID 33376347 [@pubmed | 33376347]
    Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic
    Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation sâ€¦
[4] score=0.7032 PMID 31205507 [@pubmed | 31205507]
    Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patienâ€¦
[5] score=0.7014 PMID 34045513 [@pubmed | 34045513]
    NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.
    Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. Wâ€¦</pre>
    <h3>RAG Raw Hits (JSON)</h3>
    <pre>[
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.6450715065002441,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 8,
    &quot;text&quot;: &quot;MCBS v1.1 score: 4; ESMO Scale for Clinical Actionabil-\nity of molecular Targets (ESCAT) score: I-A], niraparib\nfor 3 years [ESMO-MCBS v1.1 score: 3; ESCAT score:\nI-A] or olaparibebevacizumab for 2 years [ESMO-\nMCBS v1.1 score: 3; ESCAT score: I-A].\no For BRCA1/2-wt/HRD-positive: niraparib for 3 years\n[ESMO-MCBS v1.1 score: 3; ESCAT score: I-A] or\nolaparibebevacizumab for 2 years [ESMO-MCBS v1.1\nscore: 3; ESCAT score: I-A).\n\u0004 Maintenance treatment with either bevacizumab [I, A] or\nniraparib for 3 years [I, B; ESMO-MCBS v1.1 score: 3] can\nbe recommended for HRD-negative tumours, with the\nlatter\nfollowing\ncomplete\nor\npartial\nresponse\nto\nplatinumepaclitaxel ï¬rst-line ChT. The choice of treat-\nment should be based on disease and clinical character-\nistics of the patient.\n\u0004 Maintenance with anti-estrogen therapy after ï¬rst-line\nplatinum-based ChT can be considered in LGSC [IV, B].\nMANAGEMENT OF RECURRENT EOC\nPatient assessment\nUp to 70% of patients with stage III-IV high-grade ovarian\ncancer will relapse within 3 years. Relapse rates for early-\nstage ovarian cancer are much lower.\nSeveral factors need to be assessed when selecting a&quot;
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.6449677348136902,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esgo_esmo_esp_consensus_ovariancancer_2024__v00000000&quot;,
    &quot;page&quot;: 10,
    &quot;text&quot;: &quot;platinum-based ChT followed by niraparib or rucaparib if\nin CR/PR/NED [I, B].\nConsensus: 97% (35) yes, 0% (0) no, 3% (1) abstain (36\nvoters)\nRecommendation 13.9: When used as maintenance in\npatients in CR/PR/NED to platinum-based ChT, olaparib\n(alone or in combination with bevacizumab) and rucaparib\nare recommended for 2 years, and niraparib is recom-\nmended for 3 years [I, A].\nConsensus: 97% (34) yes, 0% (0) no, 3% (1) abstain (35\nvoters)\n14. How should older/frail patients with tubo-ovarian\ncarcinoma be investigated and treated?\nOlder patients are under-represented in clinical trials due\nto their poor performance status (PS) and comorbidities,88\nand their outcomes are poorer.89 Geriatric assessment\ngathers information on functional, mental and nutritional\nstatus, emotional conditions and social support.90 Vulner-\nability scores have been validated in clinical trials.90,91\nSurgery, frequently carried out in an emergency context\nand in unspecialised centres, is often incomplete, with\nhigher\npost-operative\ncomplications.92\nChT\nmay\nbe\nunderutilised.93,94\nRecommendation 14.1: Patients should not be excluded\nfrom diagnostic procedures, clinical trials and speciï¬c&quot;
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.6438485383987427,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 12,
    &quot;text&quot;: &quot;Version 3.2025, 07/16/25 Â© 2025 National Comprehensive Cancer NetworkÂ® (NCCNÂ®), All rights reserved. NCCN GuidelinesÂ® and this illustration may not be reproduced in any form without the express written permission of NCCN.\nNote: All recommendations are category 2A unless otherwise indicated.\nNCCN Guidelines Version 3.2025\nEpithelial Ovarian Cancer/Fallopian Tube Cancer/\nPrimary Peritoneal Cancer\nNCCN Guidelines Index\nTable of Contents\nDiscussion\nCRx/PR\nOV-5\nSTAGE II, III, IVw\nPOST PRIMARY TREATMENT\nHR\ndeficient\nHomologous\nrecombination (HR)\nproficient or status\nunknown\nOlaparib (category 1)\nor\nNiraparib (category 1)\nor\nRucaparib\nor\nObserve for select stage II disease with CR\nObserve (if CR)\nor\nNiraparib (HR deficient)\nor\nRucaparib\nor\nOlaparib (HR deficient) (category 2B)\nor\nTherapy for Persistent Disease or Recurrence (OV-7)\nMonitoring/\nFollow-up (OV-6)\nMonitoring/\nFollow-Up (OV-6)\nMAINTENANCE THERAPYh,n,y\nBevacizumab\nused as part\nof primary\ntherapy\nNo\nbevacizumab\nused during\nprimary\ntherapy\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nGermline\nor somatic\nBRCA1/2\nmutation\nBRCA1/2\nwild-type or\nunknownh\nBevacizumab + olaparib (category 1)\nor&quot;
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.6399946808815002,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;esmo_cpg_epithelialovarian_2023__v00000000&quot;,
    &quot;page&quot;: 7,
    &quot;text&quot;: &quot;A descriptive OS analysis of SOLO1 at 7-year follow-up60\nand the ï¬nal OS analysis of PAOLA-161 have shown a beneï¬t\nin OS for olaparib in patients with BRCA1/2-mutated tu-\nmours and olaparibebevacizumab in patients with HRD-\npositive tumours regardless of BRCA1/2-mut status (see\nSupplementary Material Section 3, available at https://doi.\norg/10.1016/j.annonc.2023.07.011).\nNon-high-grade serous advanced ovarian cancer. Pacli-\ntaxelecarboplatin is the standard systemic ChT used in\nLGSC, CCC and MC. Multiple retrospective studies, however,\nshowed lower response rates in these histotypes compared\nwith HGSC.62-64 Bevacizumab has shown activity in all his-\ntotypes including those less chemoresponsive, e.g. LGSC or\nCCC.49 The majority of LGSCs have high expression of es-\ntrogen receptor (ER) and progesterone receptor (PgR);\nretrospective studies suggest a possible therapeutic value of\nhormone therapy in the maintenance of newly diagnosed\nadvanced LGSC.65 This intervention is currently under\nevaluation in a prospective RCT (NCT04095364).\nRecommendations\n\u0004 Patients with advanced EOC should be evaluated for PCS\nby a specialised team, with the aim of achieving&quot;
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.6293675899505615,
    &quot;source&quot;: &quot;guideline&quot;,
    &quot;doc_id&quot;: &quot;nccn_ovariancancer_v3_2025__v00000000&quot;,
    &quot;page&quot;: 15,
    &quot;text&quot;: &quot;based chemotherapy,n\npreferred for first\nrecurrence (category 1)\nor\nRecurrence therapyn,kk\nand/or\nBest supportive care\n(See NCCN Guidelines\nfor Palliative Care)\nConsider\nsecondary\ncytoreductive\nsurgeryj,k\nImmediate platinum-based\nrecurrence therapyn (category 2B)\nand/or\nBest supportive care (See NCCN\nGuidelines for Palliative Care)\nRECURRENCE THERAPY FOR PLATINUM-SENSITIVE DISEASEn,gg,hh,ii\nMaintenance therapy (if PR or CR)\nâ€¢ Useful in certain circumstances:\n\u0017Continue bevacizumab if previously\ntreated with chemotherapy +\nbevacizumab;\nor\n\u0017PARPi therapy (for those with BRCA\n1/2 mutation)ll:\n â—ŠIf not previously used (category 1)\n â—ŠIf disease has not progressed\nduring prior PARPi treatment\nor\nObserve\ngg Data are limited on primary and maintenance therapy for recurrent/persistent LCOC.\nhh During and after treatment for recurrence, patients should be evaluated as indicated with\ntumor markers and repeat imaging (with modalities previously used) to document response\nand/or disease status.\nii Ancillary Palliative Surgical Procedures (OV-A 4 of 4).\nkk Localized RT can be considered to palliate symptoms and/or for oligometastatic disease.&quot;
  },
  {
    &quot;rank&quot;: 1,
    &quot;score&quot;: 0.7351660310039206,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;35359396&quot;,
    &quot;title&quot;: &quot;Case Report: Niraparib-Related Pulmonary Embolism During the Treatment of&quot;,
    &quot;abstract&quot;: &quot;Niraparib, an oral, potent, highly selective poly (ADP-ribose) polymerase (PARP) inhibitor, has promising clinical benefit for maintenance treatment of patients with ovarian cancer in partial response to platinum-based chemotherapy, especially in patients with BRCA mutation. In publicly available niraparib treatment-related adverse events, gastrointestinal disorders and hematological toxicities were most commonly reported with manageable safety profile. Herein, we first describe a severe and never-reported pulmonary embolism (PE) associated with the use of niraparib in a patient with BRCA mutation advanced high-grade serous ovarian cancer and received anticoagulant therapy after PE. There have been no reports of PE caused by the use of niraparib in patients with advanced high-grade serous ovarian cancer; knowledge of the occurrence of PE after the use of niraparib may assist other clinicians in managing this rare but potentially serious toxic effect.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2022-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2022.853211&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7351660310039206
  },
  {
    &quot;rank&quot;: 2,
    &quot;score&quot;: 0.7172759713714953,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;34938651&quot;,
    &quot;title&quot;: &quot;Case Report: Niraparib as Maintenance Therapy in A Patient With Ovarian Carcinosarcoma.&quot;,
    &quot;abstract&quot;: &quot;Ovarian carcinosarcoma (OCS) is a rare, highly aggressive and rapidly progressing malignant tumor with an extremely poor prognosis. So far, due to the low incidence of OCS, there are no large-scale prospective studies exploring the standard care of OCS patients. There is no uniform and effective treatment for OCS. Within the development of precision medicine, targeted therapies (such as PARP inhibitors) have been widely used in epithelial ovarian cancer and various other solid tumors. Here, we report a BRCAwt patient with advanced OCS who experienced a second and a third cytoreductive surgery in June 2017 and October 2019 and has been on niraparib maintenance therapy for more than 20 months after receiving second-line and third-line chemotherapy.&quot;,
    &quot;journal&quot;: &quot;Front Oncol&quot;,
    &quot;pub_date&quot;: &quot;2021-01-01&quot;,
    &quot;doi&quot;: &quot;10.3389/fonc.2021.603591&quot;,
    &quot;impact_factor&quot;: 3.3,
    &quot;similarity&quot;: 0.7172759713714953
  },
  {
    &quot;rank&quot;: 3,
    &quot;score&quot;: 0.7118955711747683,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;33376347&quot;,
    &quot;title&quot;: &quot;Niraparib as Maintenance Therapy in Germline ATM-mutated and Somatic&quot;,
    &quot;abstract&quot;: &quot;Brain metastases from epithelial ovarian cancer are very rare with an incidence of only 1-2.5%. Many therapeutic methods such as surgery, irradiation and chemotherapy do produce survival benefits, but the overall outcome remains unsatisfactory. The BRCA (breast cancer susceptibility gene) mutation status seems to be associated with the development of brain metastases from ovarian cancer and these patients may benefit from treatment with PARP (poly ADP ribose polymerase) inhibitors. Here is a case where a Chinese female patient diagnosed with high-grade serous ovarian cancer with brain metastases was detected to have known germline ATM mutation and somatic BRCA2 mutation. The patient underwent whole brain radiotherapy and systemic chemotherapy, commenced niraparib as maintenance treatment and then presented considerable clinical and radiological response.&quot;,
    &quot;journal&quot;: &quot;Onco Targets Ther&quot;,
    &quot;pub_date&quot;: &quot;2020-01-01&quot;,
    &quot;doi&quot;: &quot;10.2147/OTT.S281302&quot;,
    &quot;impact_factor&quot;: 2.8,
    &quot;similarity&quot;: 0.7118955711747683
  },
  {
    &quot;rank&quot;: 4,
    &quot;score&quot;: 0.7031977230437612,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;31205507&quot;,
    &quot;title&quot;: &quot;Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.&quot;,
    &quot;abstract&quot;: &quot;Poly (ADP-ribose) polymerase (PARP) inhibitors were developed with the intention of treating patients with homologous recombination repair deficiency (HRD), specifically for patients with tumours that harbour a BRCA mutation (BRCAm). Evidence from clinical trials to date has demonstrated that patients with a BRCAm derive the greatest benefit from PARP inhibitors. However, clinical studies have also shown that PARP inhibitors provide benefit to women with ovarian cancer who do not have a BRCAm. The recent updated approvals of olaparib, niraparib and rucaparib by the US Food and Drug Administration and the European Medicines Agency for the treatment of all platinum-sensitive relapsed (PSR) ovarian-cancer populations, regardless of their BRCAm status, support this. Long-term tolerability and efficacy of olaparib have been demonstrated in patients both with and without a BRCAm, with 13% of patients receiving maintenance olaparib for at least 5 years in one study, which is unprecedented in the relapsed ovarian-cancer setting (versus 1% on placebo). Further studies should be performed to elucidate which non-BRCAm patients are deriving benefit and what molecular processes are enabling this, so that patients continue to receive optimal treatment for their disease. Here, we review clinical and molecular markers of HRD, the long-term clinical safety and efficacy of PARP inhibitors in ovarian cancer, with a focus on olaparib and the current approved indications for PARP inhibitors, as well as guidance on treatment decisions for patients with PSR ovarian cancer.&quot;,
    &quot;journal&quot;: &quot;Ther Adv Med Oncol&quot;,
    &quot;pub_date&quot;: &quot;2019-01-01&quot;,
    &quot;doi&quot;: &quot;10.1177/1758835919849753&quot;,
    &quot;impact_factor&quot;: 4.2,
    &quot;similarity&quot;: 0.7031977230437612
  },
  {
    &quot;rank&quot;: 5,
    &quot;score&quot;: 0.7013539419415818,
    &quot;source&quot;: &quot;pubmed&quot;,
    &quot;pmid&quot;: &quot;34045513&quot;,
    &quot;title&quot;: &quot;NLR and BRCA mutational status in patients with high grade serous advanced ovarian cancer.&quot;,
    &quot;abstract&quot;: &quot;Laboratory-markers of the systemic inflammatory-response, such as neutrophil/lymphocyte-ratio (NLR) have been studied as prognostic factors in several tumors but in OC-patients their role is still controversial and no data about the possible correlation with the BRCA-status has been ever reported. We consecutively enrolled a series of 397 newly diagnosed high-grade serous-advanced OC-patients. All patients were tested for BRCA-mutational-status and blood-parameters have been collected 48 h before staging-surgery. A significant correlation of NLR with disease distribution (pâ€‰&lt;â€‰0.005) was found and patients with NLRâ€‰&lt;â€‰4 underwent primary-debulking-surgery more frequently (p-value 0.001), with a lower surgical-complexity-score (p-value 0.002). Regarding survival-data, patients with NLRâ€‰&lt;â€‰4 had a significant 7-month increase in mPFS (26 vs 19 months, pâ€‰=â€‰0.009); focusing on the BRCA-status, among both BRCA-mutated and BRCA-wild type patients, those with lower NLR had a significantly prolonged mPFS compared to patients with NLRâ€‰&gt;â€‰4 (BRCA-mutated: 35 vs 23 months, pâ€‰=â€‰0.03; BRCA-wt: 19 vs 16 months, pâ€‰=â€‰0.05). At multivariate-analysis, independent factors of prolonged PFS were BRCA mutational status, having received complete cytoreduction and NLRâ€‰&lt;â€‰4. Also, the strongest predictors of longer OS were BRCA-mutational status, having received complete cytoreductive surgery, NLRâ€‰&lt;â€‰4 and age. NLR is confirmed to be a prognostic marker in OC-patients and it seems unrelated with BRCA-mutational status.&quot;,
    &quot;journal&quot;: &quot;Sci Rep&quot;,
    &quot;pub_date&quot;: &quot;2021-05-27&quot;,
    &quot;doi&quot;: &quot;10.1038/s41598-021-90361-w&quot;,
    &quot;impact_factor&quot;: 3.9,
    &quot;similarity&quot;: 0.7013539419415818
  }
]</pre>
    <h3>Evidence Digest (1:1 per RAG result)</h3>
    <pre>- First-line maintenance options after response to platinum in epithelial ovarian cancer include niraparib for 3 years or olaparibâ€“bevacizumab for 2 years in BRCA-mutated or HRD-positive disease; these regimens carry high ESMO-MCBS and ESCAT I-A ratings, supporting strong clinical actionability. [1] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 8]

- Consensus guidance recommends platinum-based chemotherapy followed by PARP inhibitor maintenance (niraparib, rucaparib, or olaparib Â± bevacizumab) in patients achieving CR/PR/NED, reflecting broad expert agreement (97%) on this strategy in appropriate ovarian cancer populations. [2] [@guideline:esgo_esmo_esp_consensus_ovariancancer_2024__v00000000 | Page 10]

- NCCN identifies PARP inhibitorâ€“based maintenance as a standard component of first-line management algorithms for ovarian cancer patients responding to platinum, with recommendations generally category 2A, indicating uniform panel consensus based on lower-level evidence. [3] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 12]

- Long-term follow-up of SOLO1 and final OS data from PAOLA-1 show overall survival benefit for olaparib in BRCA-mutated tumors and for olaparibâ€“bevacizumab in HRD-positive tumors irrespective of BRCA status, reinforcing OS-driven justification for PARP-based first-line maintenance in these biomarker-selected groups. [4] [@guideline:esmo_cpg_epithelialovarian_2023__v00000000 | Page 7]

- For recurrent ovarian cancer, NCCN supports platinum-based chemotherapy for platinum-sensitive relapse and considers secondary cytoreductive surgery and best supportive care as additional options, integrating systemic therapy and surgical decisions into individualized recurrence management. [5] [@guideline:nccn_ovariancancer_v3_2025__v00000000 | Page 15]

- Case-report data indicate niraparib may be associated with venous thromboembolic events such as pulmonary embolism, highlighting the need for VTE risk assessment and monitoring when selecting and continuing niraparib maintenance. [6] [@pubmed | 35359396]

- In a reported case of ovarian carcinosarcoma, niraparib maintenance after initial therapy was feasible and showed clinical benefit, suggesting PARP inhibitors may be considered in select rare histologies when no standard-of-care options exist, especially within an individualized or trial context. [7] [@pubmed | 34938651]

- A case report of germline ATM-mutated, somatically BRCA1-mutated ovarian cancer with brain metastases demonstrated benefit from niraparib maintenance, supporting use of PARP inhibitors in selected non-classical HRD genotypes and in patients with CNS involvement when systemic control is a priority. [8] [@pubmed | 33376347]

- Evidence from trials summarized in this review supports olaparib maintenance as effective in platinum-sensitive relapsed ovarian cancer, particularly in BRCA-mutated and broader HRD populations, with significant prolongation of progression-free survival compared with placebo. [9] [@pubmed | 31205507]

- Neutrophilâ€“lymphocyte ratio was explored as a prognostic marker in high-grade serous advanced ovarian cancer and analyzed in relation to BRCA status; while data are exploratory, integration of inflammatory markers with BRCA testing may refine risk stratification but is not yet practice-changing. [10] [@pubmed | 34045513]</pre>
  </details>

  <details class='mt mermaid-container' open><summary>Pipeline Flow</summary><div class='mermaid-chart'>flowchart TD
  A[Load Case + Fingerprint] --> B[Load Reports]
  B --> C[Report Selection per Role]
  C --> D[Guideline+PubMed RAG]
  D --> E[Init Specialist Agents]
  E --> F[MDT Discussion Engine]
  F --> G[Trial Matching]
  G --> H[Final Chair Output]
  H --> I[Save Logs]</div></details>

  <details class="mt">
    <summary>Trace Events (JSON)</summary>
    <pre>[
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:43.234794&quot;,
    &quot;event&quot;: &quot;pipeline_start&quot;,
    &quot;payload&quot;: {
      &quot;visit_time&quot;: &quot;2023-01-09 09:23:13.113000&quot;,
      &quot;meta_info&quot;: &quot;310103195705270044&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:43.235316&quot;,
    &quot;event&quot;: &quot;case_fingerprint&quot;,
    &quot;payload&quot;: {
      &quot;case_fingerprint&quot;: &quot;fa2f34f1e565&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:43.722515&quot;,
    &quot;event&quot;: &quot;reports_loaded&quot;,
    &quot;payload&quot;: {
      &quot;lab_n&quot;: 152,
      &quot;img_n&quot;: 24,
      &quot;path_n&quot;: 0,
      &quot;mut_n&quot;: 1,
      &quot;cutoff_dt&quot;: &quot;2023-01-10 09:23:13&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:48.417419&quot;,
    &quot;event&quot;: &quot;reports_selected&quot;,
    &quot;payload&quot;: {
      &quot;lab&quot;: {
        &quot;chair&quot;: [
          &quot;20230109|5600622|2023-01-09&quot;,
          &quot;20230109|8300382|2023-01-09&quot;,
          &quot;20230109|9701878|2023-01-09&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;20230109|5600622|2023-01-09&quot;,
          &quot;20230109|8300382|2023-01-09&quot;,
          &quot;20230109|9701878|2023-01-09&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;imaging&quot;: {
        &quot;chair&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: [
          &quot;2022-09-27|CT|2022-09-27&quot;,
          &quot;2022-09-29|CT|2022-09-29&quot;,
          &quot;2022-10-25|MR|2022-10-25&quot;
        ]
      },
      &quot;pathology&quot;: {
        &quot;chair&quot;: [],
        &quot;oncologist&quot;: [],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [],
        &quot;nuclear&quot;: []
      },
      &quot;mutation&quot;: {
        &quot;chair&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;oncologist&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;radiologist&quot;: [],
        &quot;pathologist&quot;: [
          &quot;OH2201222|2022-01-24&quot;
        ],
        &quot;nuclear&quot;: []
      }
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:33:48.421527&quot;,
    &quot;event&quot;: &quot;rag_key_facts&quot;,
    &quot;payload&quot;: {
      &quot;facts&quot;: &quot;DIAGNOSIS: primary=Ovarian cancer; histology=High-grade serous carcinoma; components=Adenocarcinoma;High-grade serous carcinoma\nPATHOLOGY: Adenocarcinoma consistent with high-grade serous carcinoma\nPLATINUM: status=Unknown; pfi_days=Unknown\nBIOMARKERS: CA125=Unknown; AFP=Unknown; TMB=Unknown; MSI=Unknown; PDL1_CPS=Unknown\nMUTATION_REPORT: id=OH2201222; date=2022-01-24; full_text=HRD é˜³æ€§ï¼›BRCA1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRCA2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›TP53 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›ARID1A èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PTEN èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PIK3CA èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›PALB2 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›RAD51D èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BRIP1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰ï¼›BARD1 èƒšç³»å’Œä½“ç³»æœªæ£€å‡ºè‡´ç—…çªå˜ï¼ˆè§†ä¸ºé˜´æ€§ï¼‰&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:03.722822&quot;,
    &quot;event&quot;: &quot;rag_query&quot;,
    &quot;payload&quot;: {
      &quot;query&quot;: &quot;High-grade serous ovarian carcinoma, platinum-sensitive, with peritoneal and nodal metastases (6/24 nodes); HRD-positive, BRCA1/2-negative on NGS; prior niraparib maintenance limited by severe thrombocytopenia but organ function otherwise acceptable; histology: High-grade serous carcinoma&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:03.722830&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;guideline&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:03.722831&quot;,
    &quot;event&quot;: &quot;rag_hits&quot;,
    &quot;payload&quot;: {
      &quot;source&quot;: &quot;pubmed&quot;,
      &quot;topk&quot;: 5,
      &quot;n&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:03.722833&quot;,
    &quot;event&quot;: &quot;rag_hits_merged&quot;,
    &quot;payload&quot;: {
      &quot;n&quot;: 10
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:12.578670&quot;,
    &quot;event&quot;: &quot;mdt_discussion_start&quot;,
    &quot;payload&quot;: {
      &quot;num_rounds&quot;: 2,
      &quot;num_turns&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:12.578743&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;order&quot;: 1
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:17.562141&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;chair&quot;,
      &quot;chars&quot;: 552
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:17.562196&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;order&quot;: 2
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:19.914111&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;oncologist&quot;,
      &quot;chars&quot;: 506
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:19.914152&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;order&quot;: 3
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:21.729447&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;radiologist&quot;,
      &quot;chars&quot;: 483
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:21.729499&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;order&quot;: 4
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:23.840292&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;pathologist&quot;,
      &quot;chars&quot;: 526
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:23.840374&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_start&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;order&quot;: 5
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:34:25.931538&quot;,
    &quot;event&quot;: &quot;mdt_initial_opinion_role_end&quot;,
    &quot;payload&quot;: {
      &quot;role&quot;: &quot;nuclear&quot;,
      &quot;chars&quot;: 513
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:37.307415&quot;,
    &quot;event&quot;: &quot;mdt_discussion_end&quot;,
    &quot;payload&quot;: {
      &quot;merged_chars&quot;: 2302
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:37.309263&quot;,
    &quot;event&quot;: &quot;trial_matching_start&quot;,
    &quot;payload&quot;: {
      &quot;trials_json_path&quot;: &quot;files/all_trials_filtered.json&quot;
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:39.124618&quot;,
    &quot;event&quot;: &quot;trial_matching_end&quot;,
    &quot;payload&quot;: {
      &quot;recommended&quot;: false
    }
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:39.124630&quot;,
    &quot;event&quot;: &quot;final_output_start&quot;,
    &quot;payload&quot;: {}
  },
  {
    &quot;ts&quot;: &quot;2026-01-22T18:35:45.226409&quot;,
    &quot;event&quot;: &quot;final_output_end&quot;,
    &quot;payload&quot;: {
      &quot;final_output_chars&quot;: 3300
    }
  }
]</pre>
  </details>

  <!-- Mermaid.js for flowchart rendering -->
  <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
  <script>
    document.addEventListener('DOMContentLoaded', function() {
      mermaid.initialize({
        startOnLoad: true,
        theme: 'default',
        flowchart: {
          useMaxWidth: true,
          htmlLabels: true,
          curve: 'basis'
        },
        securityLevel: 'loose'
      });
      // Re-render mermaid charts in .mermaid-chart containers
      document.querySelectorAll('.mermaid-chart').forEach(function(el) {
        el.classList.add('mermaid');
      });
      mermaid.init(undefined, '.mermaid-chart');
    });
  </script>
</body>
</html>
